VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
---|---|---|---|---|---|---|---|---|
TVIS30013942 | HIV | ENSG00000105639.21 | protein_coding | JAK3 | Yes | No | 3718 | P52333 |
TVIS30074295 | HIV | ENSG00000105639.21 | protein_coding | JAK3 | Yes | No | 3718 | P52333 |
TVIS30048296 | HIV | ENSG00000105639.21 | protein_coding | JAK3 | Yes | No | 3718 | P52333 |
TVIS30048297 | HIV | ENSG00000105639.21 | protein_coding | JAK3 | Yes | No | 3718 | P52333 |
TVIS20007387 | HPV | ENSG00000105639.21 | protein_coding | JAK3 | Yes | No | 3718 | P52333 |
TVIS20007388 | HPV | ENSG00000105639.21 | protein_coding | JAK3 | Yes | No | 3718 | P52333 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
Gene | JAK3 |
---|---|
DrugBank ID | DB08877 |
Drug Name | Ruxolitinib |
Target ID | BE0003493 |
UniProt ID | P52333 |
Regulation Type | inhibitor |
PubMed IDs | 23061804; 21919691 |
Citations | Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000.@@Ostojic A, Vrhovac R, Verstovsek S: Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncol. 2011 Sep;7(9):1035-43. doi: 10.2217/fon.11.81. |
Groups | Approved |
Direct Classification | Pyrrolo[2,3-d]pyrimidines |
SMILES | N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1 |
Pathways | |
PharmGKB | PA166123386 |
ChEMBL | CHEMBL1789941 |